The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition

Trastuzumab is the only target to be approved as the first-line treatment of HER2 positive metastatic gastric cancer, but ubiquitous resistance decreases its therapeutic benefit. In this study, we found HER4, phosphorylation HER4 (p-HER4) and the mesenchymal marker Vimentin increased in trastuzumab-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncogene
Main Authors: Shi, Jiaolong, Li, Fengping, Yao, Xingxing, Mou, Tingyu, Xu, Zhijun, Han, Zheng, Chen, Siyu, Li, Wende, Yu, Jiang, Qi, Xiaolong, Liu, Hao, Li, Guoxin
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5978807/
https://ncbi.nlm.nih.gov/pubmed/29535422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-018-0204-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados